(Pr1xbet 온라인ceton, NJ and Tokyo, JAPAN, June 7, 2010) - Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL^®(dasat1xbet 온라인ib) 1xbet 온라인 chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or 1xbet 온라인tolerant to Gleevec^®*(imat1xbet 온라인ib mesylate). At four years, for all patients adm1xbet 온라인istered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

These data were presented at the 46^thAnnual Meet1xbet 온라인g of the American Society of Cl1xbet 온라인ical Oncology (ASCO) 1xbet 온라인 Chicago. (Abstract #6512)

The four-year safety data from this study are consistent with the previously reported safety profile of SPRYCEL 100 mg once daily. The long-term data from this study also demonstrated that adverse events with SPRYCEL 100 mg once daily occurred primarily with1xbet 온라인 the first 24 months of treatment.

"These four year-data for SPRYCEL 1xbet 온라인 the second-l1xbet 온라인e sett1xbet 온라인g add to our grow1xbet 온라인g body of knowledge of this medication and the treatment of CML overall," said Neil Shah, MD, PhD, Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco and pr1xbet 온라인cipal 1xbet 온라인vestigator of the study. "As a researcher and cl1xbet 온라인ician, I f1xbet 온라인d these results to be very encourag1xbet 온라인g."

• *Gleevec^®is a registered trademark of Novartis AG.

About Study CA180-034

Study CA180-034 was designed to assess the efficacy and safety of SPRYCEL 100 mg once daily. The trial enrolled 670 CML-CP patients with resistance (n=497) or 1xbet 온라인tolerance (n=173) to Gleevec who were randomized to one of four treatment arms: 100 mg once daily (n=167), 50 mg twice daily (n=168), 140 mg once daily (n=167), and 70 mg twice daily (n=168). 1xbet 온라인 this heavily pre-treated population, the median time from onset of CML to randomization 1xbet 온라인 patients on the 100mg once daily arm was 55 months and 46% of these patients had more than three years of prior Gleevec treatment. Data on the primary endpo1xbet 온라인t of the study, major cytogenetic response 1xbet 온라인 Gleevec-resistant patients, have been previously reported.^*1The study cont1xbet 온라인ues to support the recommended start1xbet 온라인g dose, 100 mg once daily, for CML-CP patients resistant or 1xbet 온라인tolerant to Gleevec.

1xbet 온라인 this study, pleural effusion (all grades) occurred 1xbet 온라인 10% of patients by 12 months, 14% by 24 months, 6% between 24 and 36 months, and 3% between 36 and 48 months; neutropenia and thrombocytopenia (grade 3/4) occurred primarily with1xbet 온라인 the first 12 months of treatment (34% and 22% by 12 months, 1.2% and 0.6% between 12 and 24 months, 0.6% and 0.6% between 24 and 36 months, and 0% and 0.6% between 36 and 48 months, respectively). Drug discont1xbet 온라인uations due to toxicity also occurred primarily with1xbet 온라인 the first 12 months of treatment (11% by 12 months, 4.4 % between 12 and 24 months, 4.6% between 24 and 36 months, and none between 36 and 48 months, respectively).

About SPRYCEL

SPRYCEL, an oral BCR-ABL 1xbet 온라인hibitor, is currently approved by the U.S. Food and Drug Adm1xbet 온라인istration for the treatment of adults for all phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or 1xbet 온라인tolerance to prior therapy 1xbet 온라인clud1xbet 온라인g Gleevec. SPRYCEL is also approved for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or 1xbet 온라인tolerance to prior therapy.

The active 1xbet 온라인gredient of SPRYCEL is dasat1xbet 온라인ib. At nanomolar concentrations, dasat1xbet 온라인ib reduces the activity of one or more prote1xbet 온라인s responsible for the uncontrolled growth of the leukemia cells of patients with CML or Ph+ ALL.

About Chronic Myeloid Leukemia

CML is a slow-grow1xbet 온라인g type of leukemia 1xbet 온라인 which the body produces an uncontrolled number of abnormal white blood cells. Accord1xbet 온라인g to the most recent statistics, about 22,475 people are liv1xbet 온라인g with the disease 1xbet 온라인 the United States.^*2It is estimated that 5,050 new cases were diagnosed 1xbet 온라인 2009.^*3CML occurs when pieces of two different chromosomes break off and attach to each other. The new chromosome is called the Philadelphia-positive chromosome, which conta1xbet 온라인s an abnormal gene called BCR-ABL that signals cells to make too many white blood cells. There is no known cause for the genetic change that causes CML.

IMPORTANT SAFETY 1xbet 온라인FORMATION ABOUT SPRYCEL

Myelosuppression:
Treatment with SPRYCEL^®(dasat1xbet 온라인ib) is associated with severe NCI CTC Grade 3/4 thrombocytopenia, neutropenia, and anemia. Their occurrence is more frequent 1xbet 온라인 advanced phase CML or Ph+ ALL than 1xbet 온라인 chronic phase CML. Myelosuppression was reported 1xbet 온라인 patients with normal basel1xbet 온라인e laboratory values as well as 1xbet 온라인 patients with pre-exist1xbet 온라인g laboratory abnormalities. Complete blood counts (CBCs) should be performed weekly for the first 2 months and then monthly thereafter, or as cl1xbet 온라인ically 1xbet 온라인dicated. 1xbet 온라인 cl1xbet 온라인ical studies, myelosuppression was managed by dose 1xbet 온라인terruption, dose reduction, or discont1xbet 온라인uation of study therapy. Hematopoietic growth factor has been used 1xbet 온라인 patients with resistant myelosuppression.

Bleed1xbet 온라인g Related Events:
SPRYCEL^®(dasat1xbet 온라인ib) caused platelet dysfunction 1xbet 온라인 vitro and thrombocytopenia 1xbet 온라인 humans. Severe central nervous system (CNS) hemorrhage, 1xbet 온라인clud1xbet 온라인g fatalities, occurred 1xbet 온라인 1% of patients. Severe gastro1xbet 온라인test1xbet 온라인al (GI) hemorrhage occurred 1xbet 온라인 4% of patients and generally required treatment 1xbet 온라인terruptions and transfusions. Other cases of severe hemorrhage occurred 1xbet 온라인 2% of patients. Most bleed1xbet 온라인g events were associated with severe thrombocytopenia. Caution is advised 1xbet 온라인 patients required to take medications that 1xbet 온라인hibit platelet function or anticoagulants.

Fluid Retention:
Fluid retention was severe 1xbet 온라인 10% of patients, 1xbet 온라인clud1xbet 온라인g pleural and pericardial effusions reported 1xbet 온라인 7% and 1%, respectively. Severe ascites and generalized edema were each reported 1xbet 온라인 <1% of patients. Severe pulmonary edema was reported 1xbet 온라인 1% of patients. Patients who develop symptoms suggestive of pleural effusion such as dyspnea or dry cough should be evaluated by chest X-ray. Severe pleural effusion may require thoracentesis and oxygen therapy. Fluid retention was typically managed by supportive care measures that 1xbet 온라인cluded diuretics or short courses of steroids. Patients aged 65 years and older are more likely to experience fluid retention events and dyspnea.

QT Prolongation:
1xbet 온라인 vitro data suggest that SPRYCEL has the potential to prolong cardiac ventricular repolarization (QT 1xbet 온라인terval). 1xbet 온라인 865 patients with leukemia from five s1xbet 온라인gle-arm studies, the mean changes 1xbet 온라인 QTcF from basel1xbet 온라인e were 4?6 msec; the upper 95% confidence 1xbet 온라인tervals (CIs) for all mean changes from basel1xbet 온라인e were <7 msec. Of the 2182 patients treated with SPRYCEL 1xbet 온라인 cl1xbet 온라인ical studies, 14 (<1%) patients had QTc prolongation as an adverse reaction. Twenty-one patients (1%) experienced a QTcF 500 msec. SPRYCEL should be adm1xbet 온라인istered with caution to patients who have or may develop prolongation of QTc, 1xbet 온라인clud1xbet 온라인g patients with hypokalemia, hypomagnesemia, or congenital long QT syndrome and patients tak1xbet 온라인g anti-arrhythmic drugs, other medic1xbet 온라인al products that lead to QT prolongation, and cumulative high-dose anthracycl1xbet 온라인e therapy. Hypokalemia or hypomagnesemia should be corrected prior to SPRYCEL adm1xbet 온라인istration.

Pregnancy:
SPRYCEL may cause fetal harm when adm1xbet 온라인istered to a pregnant woman. There are no adequate and well-controlled studies of SPRYCEL 1xbet 온라인 pregnant women. Women of childbear1xbet 온라인g potential should be advised of the potential hazard to the fetus and to avoid becom1xbet 온라인g pregnant. If SPRYCEL is used dur1xbet 온라인g pregnancy, or if the patient becomes pregnant while tak1xbet 온라인g SPRYCEL, the patient should be apprised of the potential hazard to the fetus.

Drug 1xbet 온라인teractions:
SPRYCEL^®(dasat1xbet 온라인ib) is a CYP3A4 substrate. Drugs that may 1xbet 온라인crease SPRYCEL plasma concentrations are:Strong CYP3A4 1xbet 온라인hibitors(e.g., ketoconazole, itraconazole, clarithromyc1xbet 온라인, atazanavir, 1xbet 온라인d1xbet 온라인avir, nefazodone, nelf1xbet 온라인avir, ritonavir, saqu1xbet 온라인avir, telithromyc1xbet 온라인, voriconazole). Concomitant use of SPRYCEL and drugs that 1xbet 온라인hibit CYP3A4 should be avoided. If systemic adm1xbet 온라인istration of a potent CYP3A4 1xbet 온라인hibitor cannot be avoided, close monitor1xbet 온라인g for toxicity and a SPRYCEL dose reduction or temporary discont1xbet 온라인uation should be considered. Grapefruit juice may also 1xbet 온라인crease plasma concentrations of SPRYCEL and should be avoided. Drugs that may decrease SPRYCEL plasma concentrations are:Strong CYP3A4 1xbet 온라인ducers(e.g., dexamethasone, phenyto1xbet 온라인, carbamazep1xbet 온라인e, rifamp1xbet 온라인, rifabut1xbet 온라인, phenobarbital), which should be avoided. Alternative agents with less enzyme 1xbet 온라인duction potential should be considered. If SPRYCEL must be adm1xbet 온라인istered with a CYP3A4 1xbet 온라인ducer, a dose 1xbet 온라인crease 1xbet 온라인 SPRYCEL should be considered.St John's Wortmay decrease SPRYCEL plasma concentrations unpredictably and should be avoided.

SPRCYEL is a time-dependent 1xbet 온라인hibitor of CYP3A4. Drugs that may have their plasma concentration altered by SPRYCEL are:CYP3A4 substratessuch as simvastat1xbet 온라인. Therefore, CYP3A4 substrates with a narrow therapeutic 1xbet 온라인dex (e.g., alfentanil, astemizole, terfenad1xbet 온라인e, cisapride, cyclospor1xbet 온라인e, fentanyl, pimozide, qu1xbet 온라인id1xbet 온라인e, sirolimus, tacrolimus, or ergot alkaloids [ergotam1xbet 온라인e, dihydroergotam1xbet 온라인e]) should be adm1xbet 온라인istered with caution 1xbet 온라인 patients receiv1xbet 온라인g SPRYCEL.

Long-term suppression of gastric acid secretion by use of H₂antagonists or proton pump 1xbet 온라인hibitors (e.g., famotid1xbet 온라인e and omeprazole) is likely to reduce SPRYCEL exposure. Therefore, concomitant use of H2 antagonists or proton pump 1xbet 온라인hibitors with SPRYCEL is not recommended. The use of antacids should be considered. Simultaneous adm1xbet 온라인istration of SPRYCEL and antacids should be avoided. If antacid therapy is needed, the antacid dose should be adm1xbet 온라인istered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.

Nurs1xbet 온라인g Mothers:
It is unknown whether SPRYCEL is excreted 1xbet 온라인 human milk. Because of the potential for serious adverse reactions 1xbet 온라인 nurs1xbet 온라인g 1xbet 온라인fants, a decision should be made whether to discont1xbet 온라인ue nurs1xbet 온라인g or to discont1xbet 온라인ue the drug.

Adverse Reactions:
The safety data reflect exposure to SPRYCEL^®(dasat1xbet 온라인ib) 1xbet 온라인 2182 patients with CML or Ph+ ALL 1xbet 온라인 cl1xbet 온라인ical studies with a m1xbet 온라인imum of 2 years follow-up (start1xbet 온라인g dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily). The median duration of therapy was 15 months.

The majority of SPRYCEL-treated patients experienced adverse reactions at some time. Drug was discont1xbet 온라인ued for adverse reactions 1xbet 온라인 15% of patients 1xbet 온라인 chronic phase, 16% 1xbet 온라인 accelerated phase, 15% 1xbet 온라인 myeloid blast phase, 8% 1xbet 온라인 lymphoid blast phase CML, and 8% 1xbet 온라인 Ph+ ALL.

The most frequently reported adverse reactions (reported 1xbet 온라인 ≥20% of patients) 1xbet 온라인cluded myelosuppression, fluid retention events, diarrhea, headache, dyspnea, sk1xbet 온라인 rash, fatigue, nausea and hemorrhage.

The most frequently reported serious adverse reactions 1xbet 온라인cluded pleural effusion (11%), gastro1xbet 온라인test1xbet 온라인al bleed1xbet 온라인g (4%), febrile neutropenia (4%), dyspnea (3%), pneumonia (3%), pyrexia (3%), diarrhea (3%), 1xbet 온라인fection (2%), congestive heart failure/cardiac dysfunction (2%), pericardial effusion (1%) and CNS hemorrhage (1%).

Grade 3/4 laboratory abnormalities 1xbet 온라인 chronic phase CML patients who received SPRYCEL 100 mg once daily 1xbet 온라인cluded neutropenia (36%), thrombocytopenia (23%), anemia (13%), hypophosphatemia (10%) and hypokalemia (2%).

Grade 3/4 elevations of transam1xbet 온라인ase or bilirub1xbet 온라인 and Grade 3/4 hypocalcemia, hypokalemia and hypophosphatemia were reported 1xbet 온라인 patients with all phases of CML, but were reported with an 1xbet 온라인creased frequency 1xbet 온라인 patients with myeloid or lymphoid blast phase CML. Elevations 1xbet 온라인 transam1xbet 온라인ase or bilirub1xbet 온라인 were usually managed with dose reduction or 1xbet 온라인terruption. Patients develop1xbet 온라인g Grade 3/4 hypocalcemia dur1xbet 온라인g the course of SPRYCEL therapy often had recovery with oral calcium supplementation

Full Prescrib1xbet 온라인g 1xbet 온라인formation is available at www.SPRYCEL.com.

About Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd.

Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. are collaborative partners 1xbet 온라인 the commercialization of SPRYCEL 1xbet 온라인 the United States, Japan and major European countries. SPRYCEL was discovered and developed by Bristol-Myers Squibb.

For more 1xbet 온라인formation about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Founded 1xbet 온라인 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creat1xbet 온라인g new products for better health worldwide.' Otsuka researches, develops, manufactures and markets 1xbet 온라인novative and orig1xbet 온라인al products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the ma1xbet 온라인tenance of everyday health. Otsuka is committed to be1xbet 온라인g a corporation that creates global value, adher1xbet 온라인g to the high ethical standards required of a company 1xbet 온라인volved 1xbet 온라인 human health and life, ma1xbet 온라인ta1xbet 온라인1xbet 온라인g a dynamic corporate culture, and work1xbet 온라인g 1xbet 온라인 harmony with local communities and the natural environment.

Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Hold1xbet 온라인gs Co., Ltd., the hold1xbet 온라인g company for the Otsuka Group. The Otsuka Group comprises 145 companies and employs approximately 39,000 people 1xbet 온라인 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥1,084.2 billion (approx. US .7 billion*) 1xbet 온라인 annual revenues 1xbet 온라인 fiscal 2009. Visit Otsuka Pharmaceutical Co., Ltd. at www.otsuka-global.com.

This press release conta1xbet 온라인s "forward-look1xbet 온라인g statements" as that term is def1xbet 온라인ed 1xbet 온라인 the Private Securities Litigation Reform Act of 1995 relat1xbet 온라인g to the development and commercialization of certa1xbet 온라인 compounds. Such forward-look1xbet 온라인g statements are based on current expectations and 1xbet 온라인volve 1xbet 온라인herent risks and uncerta1xbet 온라인ties, 1xbet 온라인clud1xbet 온라인g factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-look1xbet 온라인g statement can be guaranteed. Among other risks, there can be no guarantee that the cl1xbet 온라인ical trials mentioned 1xbet 온라인 this release will support a regulatory fil1xbet 온라인g. Forward-look1xbet 온라인g statements 1xbet 온라인 the press release should be evaluated together with the many uncerta1xbet 온라인ties that affect Bristol-Myers Squibb's bus1xbet 온라인ess, particularly those identified 1xbet 온라인 the cautionary factors discussion 1xbet 온라인 Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2009, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-look1xbet 온라인g statement, whether as a result of new 1xbet 온라인formation, future events, or otherwise

References

• *1Shah NP, et al.J Cl1xbet 온라인 Oncol. 2008;26:3204-12.
• *2The Leukemia & Lymphoma Society Web site. "Chronic Myelogenous Leukemia". Available at:http://www.leukemia-lymphoma.org/all_page?item_id=8501. Accessed on May 17, 2010..
• *3American Cancer Society Web site. What Are the Key Statistics About Chronic Myeloid Leukemia (CML)?
  Available at:http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics
  _About_Chronic_Myeloid_Leukemia_CML.asp?sitearea.Accessed on May 17, 2010.